Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer
Source abstract
Abstract
A multifunctional targeted nanoplatform combining photothermal therapy and chemotherapy has emerged as a promising strategy for comprehensive therapies of breast cancer. In this study, we constructed human epidermal growth factor receptor 2 (Her2)-targeted gold nanoshelled poly(lactic- co-glycolic acid) hybrid nanocapsules encapsulating perfluorooctyl bromide, superparamagnetic iron oxide nanoparticles, and doxorubicin (Her2-GPDH nanocapsules) as theranostic agent for bimodal ultrasound/magnetic resonance imaging and synergistic photothermal-chemotherapy of Her2-postive breast cancer cells. Her2–GPDH nanocomposites possessed well-defined spherical morphology, and the average diameter was about 296 nm with good dispersion. Targeting assays demonstrated that Her2–GPDH nanocapsules exhibited higher targeting binding to Her2-positive SKBR3 cells than Her2-negative MDA-MB-231cells. The encapsulation efficiency and the loading content of doxorubicin in Her2–GPDH nanocapsules were 39 ± 1.45% and 3.8 ± 0.52%, respectively, and the agent exhibited pH-responsive and near-infrared light-triggered stepwise release behavior of doxorubicin. In vitro, the agent had potential to serve as feasible candidate for ultrasound imaging and T 2 -weighted magnetic resonance imaging with a relatively high relaxivity. Cell experiments confirmed that the agent had significant photothermal cytotoxicity on SKBR3 cells, and the combined photothermal–chemotherapy could significantly enhance the anti-tumor effect. In summary, the present Her2–GPDH nanocapsules, a novel multifunctional nanoplatform, will offer a new way for early bimodal molecular-level diagnosis and synergistic treatment of Her2-positve breast cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · HER2/EGFR in Cancer Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
The Key Laboratory of Resource Chemistry of Ministry of Education, Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Normal University, Shanghai, China
Funding
National Natural Science Foundation of China
References (45)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1093/jnci/dju16510.1093/jnci/dju165 ↗
3. 10.1158/0008-5472.CAN-15-309110.1158/0008-5472.CAN-15-3091 ↗
4. 10.1002/anie.20190486010.1002/anie.201904860 ↗
5. 10.1002/cncr.2906010.1002/cncr.29060 ↗
6. 10.1038/srep4668810.1038/srep46688 ↗
7. 10.1016/j.biomaterials.2015.11.02410.1016/j.biomaterials.2015.11.024 ↗
8. 10.1039/C7NR02280H10.1039/C7NR02280H ↗
9. 10.7150/thno.881810.7150/thno.8818 ↗
10. 10.1021/nn901181c10.1021/nn901181c ↗
11. 10.1021/acsami.7b0870010.1021/acsami.7b08700 ↗
12. 10.1016/j.colsurfb.2019.05.02510.1016/j.colsurfb.2019.05.025 ↗
13. 10.1038/nature0860110.1038/nature08601 ↗
14. 10.1080/10601325.2018.148320010.1080/10601325.2018.1483200 ↗
15. 10.1016/j.jddst.2019.10128310.1016/j.jddst.2019.101283 ↗
16. 10.1002/anie.20100828610.1002/anie.201008286 ↗
17. 10.1021/ar200023x10.1021/ar200023x ↗
18. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
19. 10.2147/IJN.S4057910.2147/IJN.S40579 ↗
20. 10.1016/j.biomaterials.2011.07.00410.1016/j.biomaterials.2011.07.004 ↗
21. 10.1021/nn103575a10.1021/nn103575a ↗
22. 10.1021/nn400334y10.1021/nn400334y ↗
23. 10.1021/nn900215k10.1021/nn900215k ↗
24. 10.1016/j.addr.2010.08.00410.1016/j.addr.2010.08.004 ↗
25. Ghasemi M · Am J Nucl Med Mol Imag · 2016 · 6 · 310
26. 10.1002/smll.20130225210.1002/smll.201302252 ↗
27. 10.1039/C5TB00200A10.1039/C5TB00200A ↗
28. 10.1021/am400843d10.1021/am400843d ↗
29. 10.2147/IJN.S16490510.2147/IJN.S164905 ↗
30. 10.1016/j.jconrel.2012.04.03010.1016/j.jconrel.2012.04.030 ↗
31. 10.1016/j.biomaterials.2014.01.04110.1016/j.biomaterials.2014.01.041 ↗
32. 10.1016/j.actbio.2013.08.01810.1016/j.actbio.2013.08.018 ↗
33. 10.1080/09205063.2016.127782810.1080/09205063.2016.1277828 ↗
34. 10.1002/1521-4095(200108)13:16<1253::AID-ADMA1253>3.0.CO;2-T10.1002/1521-4095(200108)13:16<1253::AID-ADMA1253>3.0.CO;2-T ↗
35. 10.1016/j.biomaterials.2008.07.00410.1016/j.biomaterials.2008.07.004 ↗
36. 10.1021/bc049851c10.1021/bc049851c ↗
37. 10.1021/acsnano.5b0284310.1021/acsnano.5b02843 ↗
38. 10.1039/C5NR08753H10.1039/C5NR08753H ↗
39. 10.2147/IJN.S18925210.2147/IJN.S189252 ↗
40. 10.1186/s11671-019-3053-410.1186/s11671-019-3053-4 ↗
41. 10.1111/j.2042-7158.2012.01567.x10.1111/j.2042-7158.2012.01567.x ↗
42. 10.1002/adhm.20140002310.1002/adhm.201400023 ↗
43. 10.1002/adma.20040190410.1002/adma.200401904 ↗
44. 10.1002/smll.20130204210.1002/smll.201302042 ↗
45. 10.1021/nn102336310.1021/nn1023363 ↗